FDA Panel Rejects Sonablate 450 HIFU Device For Prostate Cancer
This article was originally published in The Gray Sheet
Executive Summary
The advisors voted almost unanimously that SonaCare Medical’s HIFU device did not have good enough data to support a positive risk-benefit profile, but they suggested the company could improve their trial design and try again.